Introduction
============

Osteoarthritis, which is characterized by the destruction of articular cartilage and leads to pain and loss of function, primarily in the knees and hips, is one of the most common sources of physical disability resulting in impaired quality of life ([@b1-mmr-15-05-2940]). Numerous clinical strategies, including the oral administration of nonsteroidal anti-inflammatory drugs ([@b2-mmr-15-05-2940]) and intra-articular injection of hyaluronan ([@b3-mmr-15-05-2940]), have been used to prevent the progression of osteoarthritis. Despite providing pain relief, these therapies offer limited improvement in cartilage regeneration due to the minimal blood supply, limited extracellular matrix formation and low cell density of the tissue ([@b4-mmr-15-05-2940]).

Platelet-rich plasma (PRP) is an autologous blood product, which contains concentrated platelets. The α-granules of concentrated platelets in PRP contain and release concentrated levels of growth factors, which promote chondrocyte proliferation and cartilaginous matrix secretion, including platelet-derived growth factor (PDGF), transforming growth factor (TGF), insulin-like growth factor (IGF), fibroblast growth factor (FGF) and epidermal growth factor (EGF) ([@b5-mmr-15-05-2940],[@b6-mmr-15-05-2940]). Consequently, PRP has increased in popularity over the last decade for the treatment of osteoarthritis, functioning as a growth factor delivery medium to assist in cartilage regeneration ([@b7-mmr-15-05-2940],[@b8-mmr-15-05-2940]).

Due to the increasing use of PRP in clinical practice, various protocols for PRP preparations are available, and different protocols result in PRP formulations differing in cellular composition, particularly leukocyte concentration ([@b9-mmr-15-05-2940]). It has been demonstrated that leukocyte and platelet-rich plasma (L-PRP), which has a high leukocyte concentration, also has high concentrations of pro-inflammatory cytokines, including interleukin (IL)-1β and tumor necrosis factor (TNF)-α, whereas pure platelet-rich plasma (P-PRP), which concentrates platelets and depletes leukocytes, has low or undetectable pro-inflammatory cytokine concentrations ([@b10-mmr-15-05-2940]). The stimulation of articular chondrocytes by IL-1β or TNF-α has been described to allow the nuclear translocation of NF-κB p65, which then activates the expression of a wide range of catabolic genes, including inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in chondrocytes, resulting in the production of destructive proteases and enhanced degradation of extracellular matrix ([@b11-mmr-15-05-2940],[@b12-mmr-15-05-2940]). Therefore, the high levels of IL-1β and TNF-α in L-PRP may activate the NF-κB signaling pathway to induce harmful effects on cartilage regeneration, to counter or overwhelm the beneficial effects of growth factors. However, to date, no relevant studies have substantiated this.

The aims of the present study were to evaluate the effects of L-PRP and P-PRP on extracellular matrix formation, and the NF-κB signaling pathway in human articular chondrocytes (HACs) *in vitro*.

Materials and methods
=====================

### Participant recruitment

The present study was performed in accordance with the principles of the Declaration of Helsinki. The Independent Ethics Committee of Shanghai Jiao Tong University Affiliated Sixth People\'s Hospital (Shanghai, China) approved the protocols of the study. Written informed consent was obtained from each volunteer.

A total of eight patients (six men and two women; 48--60 years old) with knee osteoarthritis were recruited for the donation of articular cartilage samples between January and February 2015. The diagnosis of knee osteoarthritis was based on the American College of Rheumatology criteria for symptomatic primary knee osteoarthritis ([@b13-mmr-15-05-2940]). In addition, 10 healthy volunteers (seven men and three women; 26--54 years old) were recruited for blood donation between February and March 2015. The inclusion criteria for this group consisted of healthy adults with no medical history of relevant diseases or consumption of any medications known to affect platelet function or concentration for 21 days prior to study commencement.

### PRP preparation

Venous blood (\~63 ml) was collected from each blood donor and anticoagulated with 7 ml acid-citrate dextrose solution A. Of the anticoagulated blood obtained, \~68 ml was used for L-PRP and P-PRP preparation in a single-donor model, 0.5 ml was used for whole blood analysis, and 1.5 ml was used for the quantification of growth factor and pro-inflammatory cytokine concentrations.

The WEGO PRP preparation system (WEGO, Shandong, China), the only commercial PRP preparation system approved by the Chinese Food and Drug Administration, was used for L-PRP preparation, according to the manufacturer\'s protocol. In brief, 28 ml of anticoagulated blood was spun at 400 x *g* for 10 min at room temperature in a specific centrifuge. Following the first spin, the blood was separated into three components: Erythrocytes at the bottom, buffy coat in the middle and platelet-containing plasma at the top. The majority of the erythrocytes were eliminated, and the resulting buffy coat and platelet-containing plasma were spun again for 10 min at 400 × *g* at room temperature. Following removal of the platelet-poor plasma supernatant, the precipitated platelets were resuspended in the residual plasma to obtain 4 ml of L-PRP.

P-PRP was prepared using a method developed in the laboratory at Shanghai Jiao Tong University Affiliated Sixth People\'s Hospital, which was demonstrated to concentrate platelets in a similar manner to the WEGO PRP preparation system, but removing the majority of leukocytes and erythrocytes (data not shown). To prepare P-PRP using this method, a 40 ml volume of the anticoagulated whole blood was spun at 160 × *g* for 10 min at room temperature in a 50-ml centrifuge tube to separate the platelet-containing plasma from the erythrocytes and buffy coat, following which the platelet-containing plasma was collected by gentle aspiration, transferred to a new tube and spun again at 250 × *g* for 15 min at room temperature. The platelet-poor plasma supernatant was discarded and the precipitated platelets were resuspended in the residual plasma to obtain 4 ml of P-PRP.

### Quantification of leukocyte and platelet concentrations

The leukocyte and platelet concentrations of the whole blood, L-PRP and P-PRP were determined via whole blood analysis using an automatic hematology analyzer (XS-800i; Sysmex Corporation, Kobe, Japan) in the clinical laboratory of Shanghai Jiao Tong University Affiliated Sixth People\'s Hospital.

### Quantification of growth factors and pro-inflammatory cytokine concentrations

The concentrations of PDGF-AB, TGF-β1, IL-1β and TNF-α in the whole blood, L-PRP and P-PRP samples were quantified according to the protocols described previously ([@b14-mmr-15-05-2940]). In brief, the whole blood, L-PRP and P-PRP samples were incubated with 10% CaCl~2~ (final concentration, 22.8 mM) at 37°C in a humidified atmosphere containing 5% CO~2~ for 7 days. At the end of the incubation period, the supernatants were collected, and the concentrations of growth factors and pro-inflammatory cytokines were determined using an enzyme-linked immunosorbent assay (ELISA) with the Quantikine Human Immunoassay kits (R&D Systems, Inc., Minneapolis, MN, USA) according to manufacturer\'s protocol.

### Isolation and treatment of HACs

The HACs were isolated according to the protocols reported previously ([@b15-mmr-15-05-2940]). In brief, articular cartilage samples were obtained from patients undergoing total knee replacement surgery, minced into small pieces and digested using 0.1% collagenase II (Sigma-Aldrich; Merck Millipore, Darmstadt, Germany) in Dulbecco\'s modified Eagle\'s medium/Ham\'s F-12 50/50 mix (DMEM/F12; Corning Life Sciences, Lowell, MA, USA). The released HACs were cultured in DMEM/F12 containing 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 1% antibiotics (10,000 U/ml penicillin and 10,000 µg/ml streptomycin; Gibco; Thermo Fisher Scientific, Inc,) at 37°C in a humidified atmosphere containing 5% CO~2~. The medium was replaced every 2 days. The cells were passaged at \~90% confluence.

HACs at the third passage were seeded a density of 2.5×10^5^/well in the lower chambers of 6-well Transwell systems (Corning Life Sciences) and divided into four groups: i) Control group, comprising cells incubated with serum-free DMEM/F12 for 24 h and then treated with DMEM/F12 supplemented with 10% FBS; ii) L-PRP group, comprising serum-starved cells, as above, treated with DMEM/F12 containing 10% L-PRP; iii) PDTC group, comprising cells serum-starved with serum-free DMEM/F12 containing 50 µM PDTC (Sigma-Aldrich; Merck Millipore) for 24 h prior to L-PRP treatment; iv) P-PRP group, comprising cells serum-starved with DMEM/F12 for 24 h and then treated with DMEM/F12 supplemented with 10% P-PRP.

PDTC is an inhibitor of the NF-κB signaling pathway and 50 µM PDTC has been reported to inhibit NF-κB activation in multiple cell lines ([@b16-mmr-15-05-2940],[@b17-mmr-15-05-2940]). The most frequently used PRP concentration in *in vitro* studies is 10%, and may be comparable to the concentration of PRP reached during *in vivo* administration ([@b18-mmr-15-05-2940]--[@b20-mmr-15-05-2940]). The PRP formulations were placed in the upper chambers of Transwell systems and activated with 10% CaCl~2~ (final concentration, 22.8 mM) to avoid direct contact between PRP clots and HACs, which were seeded in the lower chambers ([Fig. 1](#f1-mmr-15-05-2940){ref-type="fig"}) ([@b14-mmr-15-05-2940]).

### Sample collection

The cells were collected following 24 h of FBS, L-PRP or P-PRP treatment for the analysis of NF-κB p65 translocation, at 96 h for reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis and at 7 days for western blot analysis. For analyzing the production of prostaglandin E2 (PGE2), nitric oxide (NO) and glycosaminoglycan (GAG) by HACs, the medium was replaced with serum-free medium following treatment with FBS, L-PRP or P-PRP for 7 days to minimize potential artifacts due to the presence of PGE2, NO and GAG in the blood products. After 24 h, the conditioned media were collected for the analyses.

### Western blot analysis

The expression of NF-κB p65 in the nuclei of HACs was analyzed using western blot analysis. The nuclear protein extracts were prepared using an NE-PER Nuclear and Cytoplasmic Extraction Reagents kit (Thermo Fisher Scientific, Inc.) according to manufacturer\'s protocol. The total protein concentration was detected using a BCA Protein Assay kit (Pierce; Thermo Fisher Scientific, Inc.). Proteins (50 µg) were separated by 10% SDS-PAGE and subsequently transferred onto a PVDF membrane. The membranes were blocked with a solution of low-fat milk, washed three times for 5 min each with Tris-buffered saline with Tween 20 (TBST), and subsequently incubated with anti-NF-κB p65 (catalog no. 8242; Cell Signaling Technology, Inc., Danvers, MA, USA; 1:1,000) or anti-GAPDH (catalog no. 5174, Cell Signaling Technology, Inc.; 1:1,000) at 4°C overnight. Following three washes for 5 min each with TBST, the membranes were incubated with a horseradish peroxidase-conjugated anti-rabbit IgG secondary antibody (catalog no. 7074; Cell Signaling Technology, Inc.; 1:1,000) at 37°C for 1 h, followed by a further three washes for 5 min each with TBST. The blots were subjected to chemiluminescence detection using ECL western blotting substrate (Pierce; Thermo Fisher Scientific, Inc.).

The protein expression levels of cartilaginous markers, including collagen II (Col II), aggrecan and sex-determining region Y-box 9 (SOX9), in the cultured HACs were also analyzed using western blot analysis. The cells were lysed with mammalian protein extraction reagent (Pierce; Thermo Fisher Scientific, Inc.) supplemented with complete protease inhibitor. Western blot analysis was then performed, as above, using antibodies against Col II (catalog no. ab34712; Abcam, Cambridge, MA, USA; 1:5,000), aggrecan (catalog no. ab53731; Abcam; 1:500), SOX9 (catalog no. ab26414; Abcam; 1:1,000), anti-GAPDH, and anti-rabbit IgG.

### RT-qPCR analysis

RT-qPCR analysis was performed to detect the mRNA expression levels of cartilaginous markers (Col II, aggrecan and SOX9) and NF-κB-dependent inflammatory mediators (iNOS and COX-2). Total RNA was extracted from the cells using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.), and the quantity and purity were measured using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Inc.). The RT reaction was performed using EasyScript one-step gDNA Removal and cDNA Synthesis Supermix (TransGen Biotech Co., Ltd., Beijing, China) from 1 µg of total RNA, according to the manufacturer\'s protocol. The qPCR analysis was performed using TransStart Tip Green qPCR SuperMix (TransGen Biotech Co., Ltd.). The total volume of the reaction system was 10 µl, including 1 µl cDNA, 0.2 µl forward primer (10 µmol/l), 0.2 µl reverse primer (10 µmol/l), 0.2 µl 50X passive reference dye, 3.4 µl double-distilled water and 5 µl Tip Green qPCR SuperMix. The reaction conditions were as follows: 40 cycles of initiation at 95°C for 30 sec, annealing at 95°C for 5 sec, and extension at 60°C for 30 sec. GAPDH was used as a housekeeping gene for the normalization of data. The primer sequences for the target genes are listed in [Table I](#tI-mmr-15-05-2940){ref-type="table"}. Data were analyzed using the 2^−ΔΔCq^ method, as described previously ([@b21-mmr-15-05-2940]).

### Analysis of the production of PGE2, NO and GAG

The concentrations of the products of iNOS and COX-2 (NO and PGE2, respectively) and GAG in the conditioned medium were quantified via ELISA with a Quantikine Human Immunoassay kit (R&D Systems, Inc.), the Griess reaction using an NO Assay kit (Thermo Fisher Scientific, Inc.) and a 1,9-dimethylmethylene blue assay using a GAG assay kit (Biocolor, Carrickfergus, UK), respectively, according to manufacturers\' protocols. The data were calculated as fold changes compared with the control group.

### Statistical analysis

Data were collected from triplicate parallel samples and were analyzed using the Statistical Package for Social Sciences version 22.0 (IBM SPSS, Armonk, NY, USA) and presented as the mean ± standard deviation. One-way analysis of variance and the Bonferroni post-hoc test were performed to analyze the differences between groups. Pearson correlation analysis was used to analyze the linear correlations between cytokine concentrations and platelet concentrations, and the leukocyte concentrations of PRP formulations. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Components of whole blood, L-PRP and P-PRP samples

The mean leukocyte, IL-1β and TNF-α concentrations in the whole blood samples were 6.28±1.60×10^9^/l, 7.70±4.85 and 4.54±2.33 pg/ml, respectively. Compared with the whole blood, the concentrations of leukocytes in the L-PRP samples were significantly higher (36.37±9.67×10^9^/l; P\<0.001; [Fig. 2A](#f2-mmr-15-05-2940){ref-type="fig"}), as were those of IL-1β (127.32±68.07 pg/ml; P\<0.001; [Fig. 2B](#f2-mmr-15-05-2940){ref-type="fig"}) and TNF-α (53.07±34.19 pg/ml; P\<0.001; [Fig. 2C](#f2-mmr-15-05-2940){ref-type="fig"}). Although P-PRP had significantly lower concentrations of leukocytes, IL-1β and TNF-α (0.12±0.12×10^9^/l, 3.85±2.43 and 2.27±1.17 pg/ml, respectively), compared with L-PRP (P\<0.001), the differences in concentrations between P-PRP and whole blood were not significant (P=0.114; P\>0.999 and P\>0.999, respectively).

The mean platelet, PDGF-AB and TGF-β1 concentrations in the whole blood were 218.47±43.09×10^9^/l, 5.62±1.88 and 17.26±5.23 ng/ml, respectively. Compared with the whole blood, the L-PRP and P-PRP showed increased concentrations of platelets (1,202.00±369.96 and 1,258.30±224.16×10^9^/l, respectively; [Fig. 2D](#f2-mmr-15-05-2940){ref-type="fig"}), PDGF-AB (34.21±9.26 and 35.51±11.27 ng/ml, respectively; [Fig. 2E](#f2-mmr-15-05-2940){ref-type="fig"}) and TGF-β1 (98.75±29.78 and 103.58±31.41 ng/ml, respectively; [Fig. 2F](#f2-mmr-15-05-2940){ref-type="fig"}). No significant differences in concentrations of platelets, PDGF-AB or TGF-β1 were found between L-PRP and P-PRP (P\>0.999 and P\>0.999 and P\>0.999, respectively).

The results of the correlation analysis are shown in [Fig. 3](#f3-mmr-15-05-2940){ref-type="fig"}. There were significant positive correlations between the leukocyte concentrations and the IL-1β concentration (r=0.924; P\<0.001; [Fig. 3A](#f3-mmr-15-05-2940){ref-type="fig"}) and TNF-α concentration of the PRP formulations (r=0.892; P\<0.001; [Fig. 3B](#f3-mmr-15-05-2940){ref-type="fig"}). Significant positive correlations were also observed between the platelet concentration and the PDGF-AB (r=0.760; P\<0.001; [Fig. 3C](#f3-mmr-15-05-2940){ref-type="fig"}) and TGF-β1 concentrations of PRP formulations (r=0.812; P\<0.001; [Fig. 3D](#f3-mmr-15-05-2940){ref-type="fig"}). However, no significant correlations were found between the leukocyte concentrations and the PDGF-AB (r=0.028; P=0.908; [Fig. 3E](#f3-mmr-15-05-2940){ref-type="fig"}) and TGF-β1 concentrations of PRP formulations (r=0.035; P=0.882; [Fig. 3F](#f3-mmr-15-05-2940){ref-type="fig"}), or between platelet concentrations and the IL-1β (r=0.108; P=0.650; [Fig. 3G](#f3-mmr-15-05-2940){ref-type="fig"}) and TNF-α concentrations of PRP formulations (r=0.225; P=0.340; [Fig. 3H](#f3-mmr-15-05-2940){ref-type="fig"}).

### Effects of L-PRP and P-PRP on the NF-κB signaling pathway

Western blot analysis showed that P-PRP did not affect the translocation of NF-κB p65, whereas L-PRP markedly induced the accumulation of NF-κB p65 in the nuclei of HACs, which was reversed by PDTC ([Fig. 4A](#f4-mmr-15-05-2940){ref-type="fig"}). In addition, the HACs in the L-PRP group demonstrated upregulated mRNA expression levels of COX-2 (P\<0.001; [Fig. 4B](#f4-mmr-15-05-2940){ref-type="fig"}) and iNOS (P\<0.001; [Fig. 4C](#f4-mmr-15-05-2940){ref-type="fig"}), and enhanced production of PGE2 (P\<0.001; [Fig. 4D](#f4-mmr-15-05-2940){ref-type="fig"}) and NO (P\<0.001; [Fig. 4E](#f4-mmr-15-05-2940){ref-type="fig"}), compared the control group and P-PRP group. PDTC significantly inhibited these effects of L-PRP (P\<0.001). No significant differences in the mRNA expression of COX-2 or iNOS or the production of PGE2 or NO were observed among HACs in the control, PDTC and P-PRP groups. These results indicated that L-PRP may have a pro-inflammatory effect on HACs via activation of the NF-κB signaling pathway.

### Effects of L-PRP and P-PRP on extracellular matrix formation

Western blot analysis revealed that the expression levels of Col II, SOX9 and aggrecan in the cells of the PDTC group and P-PRP group were similar, but were higher, compared with those in the L-PRP group, which, in turn, were higher than those in the control group ([Fig. 5A](#f5-mmr-15-05-2940){ref-type="fig"}).

A similar trend was observed in the results of the RT-qPCR analysis. The cells in the L-PRP group had higher mRNA expression levels of Col II (P\<0.001; [Fig. 5B](#f5-mmr-15-05-2940){ref-type="fig"}), SOX9 (P=0.001; [Fig. 5C](#f5-mmr-15-05-2940){ref-type="fig"}) and aggrecan (P=0.035; [Fig. 5D](#f5-mmr-15-05-2940){ref-type="fig"}), compared with those in the control group. The cells in the PDTC and P-PRP groups had similar, but higher mRNA expression levels of all cartilaginous markers, compared with cells in the L-PRP group (P\<0.001).

In terms of the production of GAG, the cells in the PDTC and P-PRP groups secreted significantly higher levels of GAG, compared with cells in the L-PRP group (P=0.015; P=0.012, respectively), which, in turn, secreted significantly higher levels of GAG, compared with the control group (P=0.030; [Fig. 5E](#f5-mmr-15-05-2940){ref-type="fig"}). No significant difference was observed in the production of GAG between cells of the PDTC group and P-PRP group (P\>0.999).

These results demonstrated that L-PRP and P-PRP induced distinct effects on the extracellular matrix formation of HACs, with P-PRP exhibiting more marked effects. In addition, inhibiting the activation of NF-κB enhanced the effects of L-PRP to a level similar to that of P-PRP. These findings indicated that the distinct effects of L-PRP and P-PRP on the NF-κB signaling pathway may be the mechanism underlying the distinct effects of L-PRP and P-PRP on HAC extracellular matrix formation.

Discussion
==========

The platelets and growth factors, which have been detected consistently in PRP, are considered the basis of PRP therapy for cartilage regeneration. Thus, the present study quantified the platelet and growth factor concentrations to characterize L-PRP and P-PRP. PDGF-AB, which is the primary isoform of human PDGF and binds to α and β receptors, is a potent chemokine, and regulates cell proliferation and extracellular matrix deposition ([@b22-mmr-15-05-2940]). TGF-β1 has been previously shown to be involved in promoting chondrocyte anabolism *in vitro* ([@b23-mmr-15-05-2940]). In addition, *in vivo* injections of these growth factors lead to increased cartilage formation ([@b24-mmr-15-05-2940]). Although other growth factors found in PRP, including IGF, FGF and EGF, also have beneficial effects on the proliferation or extracellular matrix formation of chondrocytes, they have been found to have more variable concentrations in PRP ([@b25-mmr-15-05-2940]) and, thus, were excluded from the assays in the present study. The results showed that the L-PRP and P-PRP used in the present study concentrated platelets and, therefore, PDGF-AB and TGF-β1, compared with the whole blood. These findings were in accordance with reported previously ([@b10-mmr-15-05-2940]). Additionally, the present study found that higher growth factor concentrations of PRP formulations were significantly correlated with higher platelet concentrations, but not higher leukocyte concentrations, in the PRP formulations. These findings indicated that it was platelets, rather than leukocytes, that were the major sources of growth factors in PRP formulations.

Of note, although L-PRP had similar platelet and growth factor concentrations to P-PRP, it was not as effective as P-PRP for the promotion of extracellular matrix formation in HACs. The possible reason for this may be that L-PRP not only concentrated growth factors, which had beneficial effects on the extracellular matrix formation of HACs, but also concentrated IL-1β and TNF-α, which are known to be involved in the regulation of inflammatory responses. These findings support those of other studies demonstrating increased levels of IL-1β and TNF-α in L-PRP, and the positive correlations between leukocyte concentration and these pro-inflammatory cytokines in PRP formulations ([@b10-mmr-15-05-2940]). It has been shown in several studies that chondrocytes treated with IL-1β or TNF-α not only demonstrate increased expression of catabolic molecules, including COX-2, iNOS, matrix metalloproteinases and members of the a disintegrin and metalloproteinase with thrombospondin type 1 motifs family ([@b14-mmr-15-05-2940]), but also demonstrate inhibited extracellular matrix component synthesis ([@b26-mmr-15-05-2940]). In addition to acting independently, IL-1β and TNF-α act in synergy to induce articular cartilage destruction *in vivo* ([@b27-mmr-15-05-2940]). Furthermore, antagonists of IL-1β or TNF-α have been shown to be effective in relieving the symptoms of osteoarthritis ([@b28-mmr-15-05-2940],[@b29-mmr-15-05-2940]). These findings suggested that the concentrated leukocytes in L-PRP may release increased levels of pro-inflammatory cytokines to counter the beneficial effects of growth factors on the extracellular matrix formation of HACs. This results in the observed inferior effects of L-PRP, compared with P-PRP.

The results of the present study demonstrated that L-PRP resulted in NF-κB activation, unlike P-PRP. To the best of our knowledge, the present study is the first to demonstrate this. Several lines of evidence suggest that the NF-κB signaling pathway is intimately involved in the disturbed metabolism and enhanced catabolism of articular cartilage, which is induced by IL-1β and TNF-α ([@b30-mmr-15-05-2940]). The effects on the NF-κB signaling pathway of PRP formulations, which increase or decrease levels of IL-1β and TNF-α, have not been evaluated previously. Although platelet lysate and PRP clot releasate have been shown to inhibit activation of the NF-κB signaling pathway ([@b31-mmr-15-05-2940],[@b32-mmr-15-05-2940]), these products contain no viable leukocytes, which are concentrated in L-PRP and may be the major sources of pro-inflammatory cytokines or viable platelets, which are also concentrated in L-PRP, and P-PRP and may be the major sources of growth factors. In addition, an excess of leukocytes can overwhelm the ability of growth factors to modulate the effects of pro-inflammatory cytokines, which is considered to be the basis of the effects of platelet lysate and PRP clot releasate on the NF-κB signaling pathway ([@b33-mmr-15-05-2940],[@b34-mmr-15-05-2940]). Therefore, platelet lysate and PRP clot releasate have distinct characteristics, compared with the PRP formulations used in clinical practice, and thus, the effects of these products on the NF-κB signaling pathway may not reflect that of PRP in clinical practice.

The distinct effects of L-PRP and P-PRP on the NF-κB signaling pathway may be the mechanism underlying the distinct effects of L-PRP and P-PRP on HAC extracellular matrix formation. The findings of the present study demonstrated that PDTC, an inhibitor of NF-κB activation, which suppressed the effects of L-PRP on the NF-κB signaling pathway, enhanced the effects of L-PRP on HAC extracellular matrix formation to a level similar to that of P-PRP. Therefore, activation of the NF-κB signaling pathway may counter the beneficial effects of growth factors on extracellular matrix formation and result in the inferior effects of L-PRP, compared with P-PRP. The NF-κB signaling pathway is also involved in pain ([@b35-mmr-15-05-2940]), and inhibition of the activation of NF-κB has been advocated as a novel drug target for pain relief ([@b36-mmr-15-05-2940]). Therefore, NF-κB activation may be involved in the increased incidence of pain reaction following L-PRP injections, which is observed in clinical practice. Further investigations are required to evaluate this *in vivo*.

In conclusion, although L-PRP promoted the extracellular matrix formation of HACs, leukocytes in L-PRP may activate the NF-κB signaling pathway via the delivery of IL-1β and TNF-α to counter the beneficial effects of growth factors on HAC extracellular matrix formation, leading to inferior effects, compared with P-PRP. Thus, P-PRP may be more suitable for the treatment of osteoarthritis. Further investigations are required to evaluate these findings *in vivo* to identify a PRP formation, which is more suitable for the treatment of osteoarthritis in clinical practice.

This study was supported by a grant from the National Natural Science Foundation of China (grant no. 81401799) and a Shanghai Youth Start-up grant (grant no. 14YF1412100).
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![Concentrations of (A) leukocytes, (B) IL-1β, (C) TNF-α, (D) platelets, (E) PDGF-AB and (F) TGF-β1 of WB and PRP formulations. Data are presented as the means ± standard deviation. \*P\<0.05 between WB and PRP formulations; ^\#^P\<0.05 between L-PRP and P-PRP. WB, whole blood; L-PRP, leukocyte and platelet-rich plasma; P-PRP, pure platelet-rich plasma; IL-1β, interleukin-1β; TNF-α, tumor necrosis factor-α; PDGF-AB, platelet-derived growth factor-AB; TGF-β1, transforming growth factor-β1.](MMR-15-05-2940-g01){#f2-mmr-15-05-2940}

![Correlations between components of PRP formulations. There were significant positive correlations between leukocyte and (A) IL-1β concentration, between leukocyte and (B) TNF-α concentration, between platelet and (C) PDGF-AB concentration and between platelet and (D) TGF-β1 concentration. No significant correlations were found between leukocyte concentrations and (E) PDGF-AB or (F) TGF-β1 concentrations, or between platelet concentrations and (G) IL-1β or (H) TNF-α concentrations. L-PRP, leukocyte and platelet-rich plasma; P-PRP, pure platelet-rich plasma; TNF-α, tumor necrosis factor-α; TGF-β1, transforming growth factor-β1; IL-1β, interleukin 1β; PDGF-AB, platelet-derived growth factor-AB.](MMR-15-05-2940-g02){#f3-mmr-15-05-2940}

![Effects of PRP formulations on the NF-κB signaling pathway. (A) Western blot analysis was performed to analyze the expression of NF-κB p65 in the nucleus. Reverse transcription-quantitative polymerase chain reaction analysis was performed to detect mRNA expression levels of (B) COX-2 and (C) iNOS. The enzyme-linked immunosorbent assay and Griess reaction were performed to determine (D) PGE2 and (E) NO production, respectively. Data were normalized according to the control group. Data are presented as the mean ± standard deviation. \*P\<0.05, compared with the control group. L-PRP, leukocyte and platelet-rich plasma; P-PRP, pure platelet-rich plasma; NF-κB, NF, nuclear factor-κB; PDTC, pyrrolidine dithiocarbamate; COX-2, cyclooxygenase-2; iNOS, inducible nitric oxide synthase; PGE2, prostaglandin E2; NO, nitric oxide.](MMR-15-05-2940-g03){#f4-mmr-15-05-2940}

![Effects of PRP formulations on extracellular matrix formation. (A) Western blot analysis was performed to analyze the expression of cartilaginous markers. Reverse transcription-quantitative polymerase chain reaction analysis was performed to detect mRNA expression levels of (B) Col II, (C) aggrecan and (D) SOX9. Data were normalized according to the control group. (E) 1,9-dimethylmethylene blue assay was performed to analyze GAG production. Data are presented as the mean ± standard deviation. \*P\<0.05, compared with the control group; ^\#^P\<0.05, compared with the L-PRP group. L-PRP, leukocyte and platelet-rich plasma; P-PRP, pure platelet-rich plasma; PDTC, pyrrolidine dithiocarbamate; Col II, collagen II; SOX9, sex-determining region-box Y; GAG, glycosaminoglycan.](MMR-15-05-2940-g04){#f5-mmr-15-05-2940}

###### 

Primers sequences used for quantitative-polymerase chain reaction analysis.

  Gene       Forward primer sequence (5′-3′)   Reverse primer sequence (5′-3′)
  ---------- --------------------------------- ---------------------------------
  Col II     GACAATCTGGCTCCCAAC                ACAGTCTTGCCCCACTTAC
  Aggrecan   TCGAGGACAGCGAGGCC                 TCGAGGGTGTAGCGTGTAGAGA
  SOX9       AGCTCACCAGACCCTGAGAA              TCCCAGCAATCGTTACCTTC
  COX-2      CTTCACGCATCAGTTTTTCAAG            TCACCGTAAATATGATTTAAGTCCAC
  iNOS       GCTGCCAAGCTGAAATTGA               GATAGCGCTTCTGGCTCTTG
  GAPDH      ATCCCATCACCATCTTCC                GAGTCCTTCCACGATACCA

Col II, collagen II; SOX9, sex-determining region Y-box 9; iNOS, inducible nitric oxide synthase; COX-2, cyclooxygenase-2.
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